Rhumbline Advisers Boosts Position in Omnicell, Inc. (OMCL)
Rhumbline Advisers boosted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 1.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 75,610 shares of the company’s stock after purchasing an additional 1,394 shares during the period. Rhumbline Advisers owned about 0.20% of Omnicell worth $3,860,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Municipal Employees Retirement System of Michigan lifted its position in Omnicell by 60.6% during the third quarter. Municipal Employees Retirement System of Michigan now owns 14,100 shares of the company’s stock valued at $720,000 after purchasing an additional 5,320 shares during the period. Sei Investments Co. lifted its position in Omnicell by 76.7% during the third quarter. Sei Investments Co. now owns 8,219 shares of the company’s stock valued at $420,000 after purchasing an additional 3,567 shares during the period. BNP Paribas Arbitrage SA lifted its position in Omnicell by 58.3% during the third quarter. BNP Paribas Arbitrage SA now owns 19,093 shares of the company’s stock valued at $975,000 after purchasing an additional 7,033 shares during the period. Swiss National Bank lifted its position in Omnicell by 3.0% during the third quarter. Swiss National Bank now owns 62,200 shares of the company’s stock valued at $3,175,000 after purchasing an additional 1,800 shares during the period. Finally, Stevens Capital Management LP acquired a new position in Omnicell during the third quarter valued at $305,000. Institutional investors own 99.84% of the company’s stock.
A number of research firms recently issued reports on OMCL. Cantor Fitzgerald restated a “buy” rating and set a $60.00 target price on shares of Omnicell in a research report on Tuesday. Oppenheimer restated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research report on Tuesday. Craig Hallum restated a “buy” rating and set a $62.00 target price (up from $52.00) on shares of Omnicell in a research report on Monday, October 30th. Zacks Investment Research downgraded shares of Omnicell from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 1st. Finally, Benchmark boosted their target price on shares of Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. Omnicell currently has an average rating of “Buy” and a consensus target price of $55.14.
Omnicell, Inc. (OMCL) opened at $51.00 on Thursday. Omnicell, Inc. has a fifty-two week low of $31.85 and a fifty-two week high of $55.40. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.53 and a quick ratio of 1.08.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.42 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The company had revenue of $186.78 million during the quarter, compared to analysts’ expectations of $192.45 million. During the same quarter in the previous year, the company earned $0.40 earnings per share. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. equities research analysts expect that Omnicell, Inc. will post 0.12 EPS for the current fiscal year.
In other Omnicell news, VP Jorge R. Taborga sold 6,295 shares of Omnicell stock in a transaction on Monday, November 6th. The shares were sold at an average price of $48.69, for a total value of $306,503.55. Following the completion of the transaction, the vice president now owns 50,013 shares of the company’s stock, valued at $2,435,132.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Peter J. Kuipers sold 3,532 shares of Omnicell stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $50.96, for a total transaction of $179,990.72. Following the completion of the transaction, the vice president now directly owns 40,714 shares of the company’s stock, valued at approximately $2,074,785.44. The disclosure for this sale can be found here. Insiders sold 38,944 shares of company stock valued at $1,889,592 in the last ninety days. 3.77% of the stock is owned by corporate insiders.
WARNING: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://theolympiareport.com/2017/12/07/rhumbline-advisers-boosts-position-in-omnicell-inc-omcl.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.